(Reuters) – Merck & Co Inc said on Friday it had withdrawn its European application for Keytruda as a combination treatment for patients with an advanced stage of non-small cell lung cancer.
The company’s shares tumbled 8.9 percent to $56.50 in after-hours trading.
Earlier in the day, the U.S. drugmaker said quarterly sales of Keytruda exceeded $1 billion for the first time in the third quarter.
Reporting by Divya Grover in Bengaluru; Editing by Sriraj Kalluvila
Our Standards:The Thomson Reuters Trust Principles.